Skip to Main Content

Author Details

Zhan-Guo Gao
National Institutes of Health
1995
219
49
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36711594Anionic Phospholipids Control Mechanisms of GPCR-G Protein Recognition.bioRxiv2023
37562117Structure activity relationships of 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> serotonin receptor antagonists: N<sup>6</sup>, C2 and 5'-Modified (N)-methanocarba-adenosine derivatives.Eur J Med Chem2023
37905159Membrane Mimetic-Dependence of GPCR Energy Landscapes.bioRxiv2023
37705595First Potent Macrocyclic A<sub>3</sub> Adenosine Receptor Agonists Reveal G-Protein and β-Arrestin2 Signaling Preferences.ACS Pharmacol Transl Sci2023
37603705Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A<sub>2A</sub>/A<sub>3</sub> Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity.J Med Chem2023
35687212Fluorescent A<sub>2A</sub> and A<sub>3</sub> adenosine receptor antagonists as flow cytometry probes.Purinergic Signal2023
37382926Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y<sub>14</sub> Receptor Antagonists.J Med Chem2023
37404375A<sub>2B</sub> adenosine receptor activation and modulation by protein kinase C.iScience2023
37034662Terpenes from <i>Cannabis sativa</i> Induce Antinociception in Mouse Chronic Neuropathic Pain via Activation of Spinal Cord Adenosine A<sub>2A</sub> Receptors.bioRxiv2023
36781870Anionic phospholipids control mechanisms of GPCR-G protein recognition.Nat Commun2023
36538251Species dependence of A<sub>3</sub> adenosine receptor pharmacology and function.Purinergic Signal2023
32424811Adenosine A<sub>2A</sub> receptor antagonists: from caffeine to selective non-xanthines.Br J Pharmacol2022
35450351Selective A<sub>3</sub> Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.ACS Med Chem Lett2022
35814244Machine Learning for Discovery of New ADORA Modulators.Front Pharmacol2022
36494860Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.Arthritis Res Ther2022
36367749Structure-Activity Studies of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators.J Med Chem2022
36268115Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice.ACS Pharmacol Transl Sci2022
35983277Characterization of Dual-Acting A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gα<sub>i3</sub> and Gα<sub>oA</sub> Isoprotein Activation.ACS Pharmacol Transl Sci2022
35977382GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A<sub>2A</sub> Adenosine Receptor.J Med Chem2022
35152062Interaction of A<sub>3</sub> adenosine receptor ligands with the human multidrug transporter ABCG2.Eur J Med Chem2022
34844790A<sub>3</sub> adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity.Eur J Med Chem2022
33422981Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition.Eur J Med Chem2021
35480676Convergent synthesis of 2-thioether-substituted (<i>N</i>)-methanocarba-adenosines as purine receptor agonists.RSC Adv2021
33738064Biological Evaluation of 5'-(<i>N</i>-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors.ACS Med Chem Lett2021
33831560Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y<sub>6</sub> receptor antagonists.Bioorg Med Chem Lett2021
34469110Discovery of Highly Potent Adenosine A<sub>1</sub> Receptor Agonists: Targeting Positron Emission Tomography Probes.ACS Chem Neurosci2021
34435786Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A<sub>3</sub> Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary.J Med Chem2021
34734588Fragment-based design of selective GPCR ligands guided by free energy simulations.Chem Commun (Camb)2021
34713378Pharmacological characterization of DPTN and other selective A<sub>3</sub> adenosine receptor antagonists.Purinergic Signal2021
34171656Synthesis and evaluation of adenosine derivatives as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A<sub>3</sub> agonists.Eur J Med Chem2021
32125824Correction to Accelerating the Throughput of Affinity Mass Spectrometry-Based Ligand Screening toward a G Protein-Coupled Receptor.Anal Chem2020
34163862Ligand design by targeting a binding site water.Chem Sci2020
31787357Conjugable A<sub>3</sub> adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes.Eur J Med Chem2020
33062176Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A<sub>3</sub> Receptor Agonists.ACS Med Chem Lett2020
33129204Nucleotide P2Y<sub>1</sub> receptor agonists are in vitro and in vivo prodrugs of A<sub>1</sub>/A<sub>3</sub> adenosine receptor agonists: implications for roles of P2Y<sub>1</sub> and A<sub>1</sub>/A<sub>3</sub> receptors in physiology and pathology.Purinergic Signal2020
32787142Exploration of Alternative Scaffolds for P2Y<sub>14</sub> Receptor Antagonists Containing a Biaryl Core.J Med Chem2020
32271569Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A<sub>3</sub> Adenosine Receptors: Affinity Enhancement by <i>N</i><sup>6</sup>-(2-Phenylethyl) Substitution.J Med Chem2020
32408534Allosteric Antagonism of the A<sub>2A</sub> Adenosine Receptor by a Series of Bitopic Ligands.Cells2020
32224136Assessment of biased agonism at the A<sub>3</sub> adenosine receptor using β-arrestin and miniGα<sub>i</sub> recruitment assays.Biochem Pharmacol2020
30605331Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.J Med Chem2019
31627281A<sub>2B</sub> Adenosine Receptor and Cancer.Int J Mol Sci2019
30983976Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development.Front Cell Neurosci2019
31094506Accelerating the Throughput of Affinity Mass Spectrometry-Based Ligand Screening toward a G Protein-Coupled Receptor.Anal Chem2019
28682469A<sub>3</sub> Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.Med Res Rev2018
30038283Author Correction: Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y<sub>1</sub> and P2Y<sub>12</sub> receptors.Sci Rep2018
29874058Extrinsic Tryptophans as NMR Probes of Allosteric Coupling in Membrane Proteins: Application to the A2A Adenosine Receptor.J Am Chem Soc2018
30292756Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives.Biochem Pharmacol2018
30568760Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A<sub>3</sub> adenosine receptor antagonists.Medchemcomm2018
30359014Preclinical Evaluation of the First Adenosine A<sub>1</sub> Receptor Partial Agonist Radioligand for Positron Emission Tomography Imaging.J Med Chem2018
30411015Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists.ACS Omega2018
  • 1 - 50 of 219

Recommended Authors

Ryan H Gumpper
UNC School of Medicine
Career Start Year 2015
Number of shared co-authors 1
Joel Karpiak
Department of Pharmaceutical Sciences, University of California San Francisco
Career Start Year 2009
Number of shared co-authors 2
Andrew C Kruse
Blavatnik Institute, Harvard Medical School
Career Start Year 2008
Number of shared co-authors 2
Bryan L Roth
UNC School of Medicine
Career Start Year 2006
Number of shared co-authors 1
Carmen Abate
Polish Academy of Sciences
Career Start Year 2004
Number of shared co-authors 3
Bartosz Balana
Janssen Research and Development LLC, Janssen Pharmaceutica N.V.
Career Start Year 2003
Number of shared co-authors 1
Noel Southall
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 1
Jeffrey G Varnes
Oncology R&D
Career Start Year 2002
Number of shared co-authors 0
Vincent Setola
West Virginia University School of Medicine
Career Start Year 2001
Number of shared co-authors 4
William H Bisson
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2001
Number of shared co-authors 1
Christopher J Langmead
Monash University
Career Start Year 2000
Number of shared co-authors 1
Anthony B Pinkerton
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2000
Number of shared co-authors 0
Anne Marinier
Institute for Research in Immunology and Cancer
Career Start Year 1997
Number of shared co-authors 0
Methvin Isaac
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1997
Number of shared co-authors 0
Michael Ohlmeyer
Atux Iskay LLC
Career Start Year 1993
Number of shared co-authors 1
Xi-Ping Huang
University of North Carolina School of Medicine
Career Start Year 1992
Number of shared co-authors 11
Eric L Barker
Purdue University
Career Start Year 1991
Number of shared co-authors 0
Mark Namchuk
Blavatnik Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 0
Howard Broughton
Lilly Research Laboratories
Career Start Year 1990
Number of shared co-authors 1
Stephen L Yates
UCB Pharma
Career Start Year 1990
Number of shared co-authors 0
Christopher P Austin
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 3
Sally Freeman
Division of Pharmacy and Optometry, University of Manchester
Career Start Year 1988
Number of shared co-authors 0
Antonio Macchiarulo
Department of Pharmaceutical Sciences, University of Perugia
Career Start Year 1986
Number of shared co-authors 0
Joel Morris
National Cancer Institute
Career Start Year 1986
Number of shared co-authors 0
Robert J Ardecky
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1985
Number of shared co-authors 0
Debra A Schwinn
Roy J. & Lucille A. Carver College of Medicine, University of Iowa
Career Start Year 1981
Number of shared co-authors 0
Michel Bouvier
Institute for Research in Immunology and Cancer, Universite de Montreal
Career Start Year 1981
Number of shared co-authors 5
Bryan L Roth
UNC Chapel Hill School of Medicine
Career Start Year 1980
Number of shared co-authors 13
Wolfgang Sad??e
College of Medicine, The Ohio State University
Career Start Year 1967
Number of shared co-authors 0
Francesco Berardi
Universita degli Studi di Bari
Career Start Year 1965
Number of shared co-authors 3

Collaborators

Kenneth A Jacobson
National Institutes of Health
Co-authored papers 207
John A Auchampach
Co-authored papers 21
Khai Phan
Co-authored papers 17
Raymond C Stevens
iHuman Institute, ShanghaiTech University
Co-authored papers 15
Steven M Moss
University of California San Francisco
Co-authored papers 12
Jens Carlsson
Uppsala University
Co-authored papers 8
Gye Won Han
Bridge Institute, University of Southern California
Co-authored papers 7
Kai Ye
Co-authored papers 3
Kaihua Zhang
Henan Normal University
Co-authored papers 3
T K Harden
Co-authored papers 3
Hualiang Jiang
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Co-authored papers 3
Bingjie Zhang
JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine
Co-authored papers 2
Suwen Zhao
ShanghaiTech University, China iHuman Institute
Co-authored papers 2
Kurt W??thrich
iHuman Institute, ShanghaiTech University
Co-authored papers 2
Wenqing Shui
iHuman Institute, ShanghaiTech University
Co-authored papers 2
Kate L White
Lawrence Berkeley National Laboratory
Co-authored papers 2
Andrej Sali (CM4AI)
University of California San Francisco
Co-authored papers 1
Adam C Marko
Co-authored papers 1
Dale O Kiesewetter
National Institute of Biomedical Imaging and Bioengineering
Co-authored papers 1
Peter Kolb
Institut fur Pharmazeutische Chemie, Philipps-Universitat Marburg
Co-authored papers 1
Kyle M McClary
Bridge Institute, University of Southern California
Co-authored papers 1
John M Streicher
Co-authored papers 1
John J Irwin
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Brian K Shoichet
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 1
Lixin Lang
First Hospital of Shanxi Medical University, Shanxi Medical University
Co-authored papers 1
Ying Ma
National Institutes of Health
Co-authored papers 1
Daniel H Fowler
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Abesh Kumar Bhattacharjee
University of California San Diego.
Co-authored papers 1
Craig J Thomas
Center for Cancer Research, National Cancer Institute
Co-authored papers 1
Ruben Abagyan
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Co-authored papers 1
Release 1.2